Nordson EFD Introduces New Fluid Dispensing Guide for Machine Builders
Nordson EFD, a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, is pleased to introduce a new Machine Builder Solutions Guide and Dispense Valve Selection Guide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190227005019/en/
Nordson EFD offers more than 130 types of valves for nearly any type of fluid and application requirement. (Photo: Business Wire)
These guides are designed to make it easier for custom automation providers to understand and select the right fluid dispensing systems for end-users. The solutions guide includes testimonials and links to useful resources such as 3D and 2D CAD models of Nordson EFD valves, controllers, dispense tips, tanks, components, fittings, and more.
It also includes several application examples with recommended dispense valves and controllers. Find out how to register for a complimentary application test. Discover why it’s important to get an application specialist involved early in a project to avoid common pitfalls.
The valve selection guide allows users to find the right valve based on the fluid being dispensed and the dispense pattern required. It includes valve and controller comparison grids that allow machine builders to compare features and specifications to better identify the right solution. It also includes a fluid reservoir comparison grid, which provides recommendations based on fluid viscosity and production volume.
“As products and solutions grow in complexity, machine builders face increasing demands to design custom automation systems that boost productivity and business agility while lowering cost of ownership for end-users,” said Claude Bergeron, product line manager of valves at Nordson EFD. “We understand the challenges they face, and we provide a wide range of reliable dispensing systems along with 50+ years of application expertise to help them meet those challenges.”
For more information, email Nordson EFD at info@nordsonefd.com, or call +1 401.431.7000 or 800.556.3484.
About Nordson EFD
Nordson EFD designs and manufactures precision fluid dispensing systems for benchtop assembly processes and automated assembly lines. By enabling manufacturers to apply the same amount of adhesive, lubricant or other assembly fluid to every part, every time, EFD dispensing systems are helping companies in a wide variety of industries increase throughput, improve quality, and lower their production costs. Other fluid management capabilities include high-quality syringe barrels and cartridges for packaging one- and two-component materials, along with a wide variety of fittings, couplers and connectors for controlling fluid flow in medical, biopharmaceutical and industrial environments. The company is also a leading formulator of specialty solder pastes for dispensing and printing applications in the electronics industry.
About Nordson Corporation
Nordson engineers, manufactures, and markets differentiated products and systems used for dispensing and processing adhesives, coatings, polymers, sealants and biomaterials; and for managing fluids, testing and inspecting for quality, treating surfaces and curing. These products are supported with extensive application expertise and direct global sales and service. We serve a wide variety of consumer non-durable, consumer durable and technology end markets including packaging, nonwovens, electronics, medical, appliances, energy, transportation, building and construction, and general product assembly and finishing. Founded in 1954 and headquartered in Westlake, Ohio, the company has operations and support offices in more than 30 countries. Visit Nordson on the web at nordson.com, twitter.com/Nordson_Corp or facebook.com/nordson.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190227005019/en/
Contact information
Natalie Tomasso
Marketing Communications Specialist
+1-401-431-7173
(USA)
natalie.tomasso@nordsonefd.com
For more information contact:
Nordson EFD
Global
Natalie Tomasso
+1-401-431-7173; natalie.tomasso@nordsonefd.com
Europe
+44 (0) 1582 666334; europe@nordsonefd.com
China
+86 (21) 3866 9006; china@nordsonefd.com
Japan
+81 (03) 5762 2760; japan@nordsonefd.com
Korea
+82 (31) 7368321; korea@nordsonefd.com
SEAsia
+65 6796 9522; sin-mal@nordsonefd.com
India
+91 80 4021 3600; india@nordsonefd.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz ® ) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 01:45:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer (SCAC) who have not been previously treated with systemic chemotherapy, were published in The Lancet.1 “The publication of the POD1UM-303/InterAACT 2 trial in The Lancet is a testament to the strength of the data generated for retifanlimab in patients with inoperable locally recurrent or metastatic SCAC, a disease which until recently had seen limited innovation for decades,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “SCAC can be a devastating disease, and patients often have a poor prognosis. These data supported the U.S. Food and Drug Administration (FDA) approval of Zynyz® (retifanl
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 22:30:00 EEST | Press release
Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal, but a core driver of innovation. Key milestones include a near-complete transition to natural refrigerants
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 21:45:00 EEST | Press release
Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of European enterprises, providing a framework for high performance in even the most complex, secure environments. “With about 6 million developers across Europe, users deserve infrastructure that meets them where they are,” said Varun Mohan, CEO of Windsurf. “The demand for secure AI-powered development is undeniable and by launching this GPU cluster, we aim to b
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 20:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization journey, allowing developers to focus on building engaging games, not commerce infrastructure. This SDK connects three
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 18:00:00 EEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom